Partnering for Global Health
The value Sanofi has always placed on partnership is one of the reasons we are the global healthcare leader we are today. Some of our most well-known therapies, Plavix®, Ambien®, Taxotere® and Eloxatin®, are the result of partnerships, as is more than half of our current development portfolio. This heritage sustains our commitment to bring partnership into every sector of our business, a commitment that has resulted in collaborations with some of the world’s foremost scientific organizations. Partnership is in our DNA.
We are a diversified global healthcare leader, focused on the growing needs of patients, regulators and payers to improve healthcare outcomes innovatively and cost effectively. Like you, we are driven by our passion to transform scientific innovation into hope and solutions. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme, which focuses on rare diseases and multiple sclerosis.
Our international presence and broad range of scientific expertise are world class. Even so, we are aware that no company has a monopoly on innovation and that there is no single way to advance a new idea.
Because any one target or pathway may impact multiple disease states, Sanofi welcomes innovative partnerships for all types of therapies in all therapeutic areas. We are committed to creating an open and creative partnership model. If you are working on something new with potential value for patients, we encourage you to contact us.
American Diabetes Association (ADA) 73rd Scientific Sessions 2013
June 21-25, 2013
Partnering press releases
March 25, 2013
© Sanofi 2004-2013 - All rights reserved - Update: November 13, 2012